Radionuclide-Drug Conjugates (RDCs)
Radionuclide-drug conjugates (RDCs) are one of the most promising development directions for nuclear drug targeted therapy. RDC is composed of targeting element, linker, chelate and radioactive isotope. RDC has advantages in early tumor diagnosis, treatment and postoperative tumor evaluation. The same ligand can be connected to nuclides used for disease diagnosis and treatment respectively, promoting the integration of diagnosis and treatment of RDC drugs. This entry provides molecular intermediates that can be used in the synthesis and research of RDC.
Radionuclide-Drug Conjugates (RDCs) Isoform Specific Products
All Product Categories
-
Radionuclide-Drug Conjugates (RDCs) Related Products (230)
Related Products (230)
-
Radionuclide-Drug Conjugates (RDCs) Isoform Comparison
-
DOTAEt
0 ImagesCat. No.: HY-164653CAS No.: 137076-50-7DOTAEt is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy.
-
Hynic-toc
0 ImagesCat. No.: HY-P10232CAS No.: 257943-19-4Synonyms: HYNIC-Tyr3-octreotideHynic-toc (HYNIC-Tyr3-octreotide), a octreotide derivative, can be conjugated with radioactive element for tumor imaging. Hynic-toc can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
-
CD73-IN-22
0 ImagesCat. No.: HY-181919CD73-IN-22 (Compound HX-6) is a non-nucleoside CD73 inhibitor with an IC50 of 0.07 μM. When radiolabeled with 68Ga, CD73-IN-22 acts as a PET radiotracer for detecting CD73 expression. When radiolabeled with 177Lu, CD73-IN-22 exhibits anticancer activity against colorectal adenocarcinoma. CD73-IN-22 is applicable to research related to colon adenocarcinoma and breast cancer.
-
MIP-1095
0 ImagesCat. No.: HY-123733CAS No.: 949575-22-8Synonyms: RPS-001MIP-1095 (RPS-001) is a PSMA inhibitor with a Ki value of 0.24 nM. MIP-1095 binds to PSMA with high affinity and can be internalized into PSMA-expressing cancer cells. When radiolabeled with 123I, 124I or 131I, MIP-1095 enables SPECT/CT imaging, PET/CT imaging or targeted radiation delivery, respectively. 131I-MIP-1095 can alter serum PSA levels and relieve bone pain. MIP-1095 can be used in research related to metastatic castration-resistant prostate cancer.
-
3p-C-NOTA
0 ImagesCat. No.: HY-164603CAS No.: 2166455-20-33p-C-NOTA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy.
-
cRY9M
0 ImagesCat. No.: HY-P11853cRY9M is a cyclic peptide that binds to FGFR1, with a KD value of 58 nM. cRY9M binds specifically to FGFR1, exhibits enhanced in vivo stability, and shows extremely low degradation in blood, urine and liver homogenate after injection. cRY9M displays significant specific uptake in FGFR1-positive tumor xenograft models, while its uptake decreases in FGFR1-negative tumor models and blocking models. The NOTA-chelated precursor of cRY9M can be labeled with 68Ga to obtain [68Ga]Ga-NOTA-cRY9M, which is used for research on non-invasive imaging of FGFR1 expression in non-small cell lung cancer.
-
Cys-FAP targeting peptide for FXX489
0 ImagesCat. No.: HY-P10945ACys-FAP targeting peptide for FXX489 is a FAP-targeting peptide for FXX489 (HY-P10945) that incorporates a Cys (cysteine) residue. It can undergo conjugation reactions via the thiol group of the cysteine residue.
-
CTB006
0 ImagesCat. No.: HY-P992340CTB006 is a monoclonal antibody targeting a humanized chimeric recombinant anti-DR5. CTB006 specifically binds to and activates DR5, thereby inducing tumor cell apoptosis, inhibiting tumor growth and reducing tumor drug resistance. 177Lu-radiolabeled CTB006 can deliver targeted radiotherapy to tumor cells; while 89Zr- or 177Lu-labeled CTB006 can serve as a PET/CT imaging agent for detecting DR5 expression levels in preclinical tumor models and screening cancers with DR5 overexpression. CTB006 can be applied to research related to gastrointestinal cancer, colorectal cancer and other solid tumors.
-
Fluoroclebopride
0 ImagesFluoroclebopride is a Dopamine receptor ligand with a binding Ki of 0.95 nM for the dopamine D2 receptor and a binding Ki of 5.46 nM for the dopamine D3 receptor. When radiolabeled with 18F, Fluoroclebopride can be used to detect the availability of dopamine D2 and D3 receptors in the caudate nucleus and putamen of primates.
-
NH2-NODAGA
0 ImagesCat. No.: HY-164575CAS No.: 1630114-57-6NH2-NODAGA is an amino-modified NODAGA-type bifunctional chelator, specifically designed for amidation coupling with targeting ligands via squaric acid (SA), followed by coordination with radionuclides (e.g., 68Ga, 177Lu). NH2-NODAGA can be coupled with diethyl squarate to form a PSMA inhibitor conjugate, which is used in prostate cancer research.
-
DP1 peptide
0 ImagesCat. No.: HY-P11858DP1 peptide is a high-affinity ROR1-binding peptide with a Kd value of 74.9 nM. When labeled with 68Ga, DP1 peptide serves as a PET imaging agent, which features rapid tumor uptake, favorable target-to-nontarget ratios in various tumor models, and renal clearance, enabling non-invasive quantitative visualization of ROR1 expression. DP1 peptide can be used in research related to melanoma, hepatocellular carcinoma, colorectal cancer, and non-small cell lung cancer.
-
2,3,5,6-Tetrafluorophenyl propionate-PEG3-amino-tetraxetan
0 ImagesCat. No.: HY-167790CAS No.: 2247041-83-22,3,5,6-Tetrafluorophenyl propionate-PEG3-amino-tetraxetan is a chelating agent and linker conjugate that can be used in the synthesis of radiopharmaceuticals.
-
DOTA-Pep-1L
0 ImagesCat. No.: HY-P11287DOTA-Pep-1L is a polypeptide formed by the conjugation of DOTA and Pep-1L. DOTA-Pep-1L specifically binds to IL13RA2 and can be used for the synthesis of targeted polypeptides. DOTA-Pep-1L yields the isotopically labeled product [225Ac]DOTA-Pep-1L, which exerts α-radiation killing effects on orthotopic glioma cells and extends the median survival time of mice bearing orthotopic glioma models after stereotactic injection. DOTA-Pep-1L can be used for PET imaging, tumor targeting and glioma research.
-
BQ7876
0 ImagesCat. No.: HY-P10743BQ7876 is a probe targeting prostate-specific membrane antigen (PSMA) that contains a DOTA chelator. BQ7876, after being radiolabeled with radionuclide (177Lu), functions in both radionuclide imaging and tumor cell destruction by specifically binding to PSMA. BQ7876 shows potential for research in the field of metastatic castration-resistant prostate cancer (mCRPC). BQ7876 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
-
NM404
0 ImagesCat. No.: HY-182387CAS No.: 208986-26-9NM404 is a targeted radionuclide processing agent with slow clearance. Radioiodine-labeled NM404 is a small-molecule phospholipid ether analog that exhibits significant tumor uptake capacity and persistent tumor retention properties in more than 45 spontaneous and xenograft tumor models.
-
Propargyl-NOTA(tBu)2
0 ImagesCat. No.: HY-W999766CAS No.: 1924677-40-6Propargyl-NOTA(tBu)2 is a bifunctional chelating ligand that can bind to radionuclides to prepare radionuclide conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging.
-
SU015
0 ImagesCat. No.: HY-P3335CAS No.: 250612-06-7Synonyms: DOTA-RGDfK dimerSU015 (DOTA-RGDfK dimer) is a Integrin αvβ5 and αvβ3 antagonist. SU015 exhibits comparable affinity for αvβ5 and αvβ3, with relatively higher potency and specificity compared to other integrins. SU015 inhibits αvβ3-mediated cell adhesion to fibrinogen, αvβ3-mediated adhesion of activated platelets to osteopontin, and αvβ5-mediated cell adhesion to vitronectin. SU015 shows potent inhibitory effects on FGF2-induced angiogenesis in the CAM model. SU015 carries a linker arm available for radioisotope conjugation, and acts as a target-specific radioreagent when labeled with 90Y (i.e., RP697) or 177Lu (i.e., RP688). SU015 can be used in studies related to tumor metastasis and tumors.
-
NO2A-(t-Bu ester)
0 ImagesCat. No.: HY-W717833CAS No.: 174137-97-4NO2A-(t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. NO2A-(t-Bu ester) can be used for conjugation of peptides and radionuclides.
-
Pentixafor peptide cyclo(dTyr-dOrn(NMe)-R-Nal-G)
0 ImagesCat. No.: HY-P11451CAS No.: 1339959-27-1Pentixafor peptide cyclo(dTyr-dOrn(NMe)-R-Nal-G) is a peptide that targets CXCR4. Pentixafor peptide cyclo(dTyr-dOrn(NMe)-R-Nal-G) constitutes the peptide moiety of Pentixafor (HY-153549). Pentixafor is a highly selective cyclic pentapeptide ligand targeting the CXCR4 receptor and is suitable for research into radionuclide-drug conjugates (RDCs).
